Corporate Information

• 19 Oct, 2023
  Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien
• 19 Oct, 2023
  Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia
• 5 Oct, 2023
  Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)
• 28 Jun, 2023
  Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02
• 28 Jun, 2023
  Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02
• 13 Jun, 2023
  Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board
• 13 Jun, 2023
  Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd
• 23 May, 2023
  Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study
• 23 May, 2023
  Spago Nanomedical har lämnat in ansökan om att starta klinisk fas I/IIa-studie med Tumorad®